From Utah, USA:
Looking for information on Captopril's beneficial effects on diabetic nephropathy. Is there wisdom in initiating therapy before signs of kidney disease manifest?
It is now very clear that following a strict set of guidelines can help protect kidney function in people with diabetes who have diabetic kidney disease.
It is also known that prevention efforts, especially tight control of blood sugar, will also help people with diabetes who don't have any evidence of kidney problems to cut the chance of getting kidney disease.
Captopril (which is sold in the USA as a generic drug, and under the brand name Capoten) has also been considered as a possibility to be used in prevention of diabetic nephropathy. There are studies underway to see if it might be wise to use captopril before any evidence of kidney disease or hypertension develops.
It (or other similar drugs in the same class, called ACE inhibitors) is routinely recommended in diabetic patients with hypertension, and is frequently used as soon as evidence of any diabetic kidney malfunction is found, but so far, it is not recommended in the absence of kidney malfunction or hypertension, since it's difficult to decide who will get kidney problems and who will not, and using Capoten in every patient exposes everyone to risks and expenses that are not yet shown to be worthwhile.
For more information, see How to Protect your Kidneys.
Original posting 6 Oct 96
|Return to the Top of This Page|
Last Updated: Tuesday April 06, 2010 15:08:52
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.